Literature DB >> 18795303

High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins.

Lian Zhang1, Hui Zhu, Chengbin Jin, Kun Zhou, Kequan Li, Haibing Su, Wenzhi Chen, Jin Bai, Zhibiao Wang.   

Abstract

Hepatocellular carcinoma (HCC) is an especially frequent malignancy in China. Radiofrequency ablation, percutaneous ethanol injection, transarterial chemoembolization, cryoablation, microwave coagulation, and laser-induced interstitial thermotherapy all offer potential local tumor control and occasionally achieve long-term disease-free survival. High-intensity focused ultrasound (HIFU), as a noninvasive therapy, can be applied to treat tumors that are difficult to treat with other techniques. The preliminary results of HIFU in clinical studies are encouraging. The aims of this investigation were to assess the efficacy of the system in obtaining necrosis of the target tissue and to determine whether HIFU ablation is hazardous to adjacent major blood vessels. Over 7 years, thirty-nine patients with HCC were enrolled in this investigation. The inferior vena cava (IVC), main hepatic vein branches, and the portal vein and its main branches were evaluated. The distance between tumor and main blood vessel was less than 1 cm in all these enrolled patients. Contrast-enhanced MRI was used to evaluate the perfusion of tumors and major blood vessels. We conducted HIFU ablation for the treatment of 39 patients with 42 tumors, with each tumor measuring 7.4+/-4.3 (1.5-22) cm in its greatest dimension. Among the 39 patients, 23 were males and 16 females. The average age was 53.2 years (range 25-77 years). Thirty-seven patients had a solitary lesion, one had two lesions, and the remaining one had three lesions. Nineteen lesions were located in the right lobe of liver, 18 in the left lobe, and 5 in both right and left lobes. Among the 42 tumors, 25 were adjacent to 1 blood vessel, 12 adjacent to 2 main vessels, 2 adjacent to 3 main vessels, and 1 adjacent to 4 main vessels. Twenty-one of the 42 tumors were completely ablated, while the rest of the tumors were ablated by more than 50% of lesion volume after one session of HIFU. No major blood vessel injury was observed in any subject after 23.8+/-17.2 months follow-up. HIFU can achieve complete tumor necrosis even when the lesion is located adjacent to the major hepatic blood vessels. Short-term and long-term follow-up results show that HIFU can be safely used to ablate the tumors adjacent to major vessels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795303     DOI: 10.1007/s00330-008-1137-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma.

Authors:  H P Allgaier; P Deibert; I Zuber; M Olschewski; H E Blum
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

3.  Production of focal destructive lesions in the central nervous system with ultrasound.

Authors:  W J FRY; W H MOSBERG; J W BARNARD; F J FRY
Journal:  J Neurosurg       Date:  1954-09       Impact factor: 5.115

4.  Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size.

Authors:  E J Patterson; C H Scudamore; D A Owen; A G Nagy; A K Buczkowski
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

5.  Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.

Authors:  Riccardo Lencioni; Dania Cioni; Laura Crocetti; Chiara Franchini; Clotilde Della Pina; Jacopo Lera; Carlo Bartolozzi
Journal:  Radiology       Date:  2005-01-21       Impact factor: 11.105

6.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Authors:  G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

7.  Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study.

Authors:  Kentaro Yamagiwa; Katsuya Shiraki; Koichiro Yamakado; Shugo Mizuno; Tomohide Hori; Shinichiro Yagi; Takashi Hamada; Taku Iida; Ikuo Nakamura; Koji Fujii; Masanobu Usui; Shuji Isaji; Keiichi Ito; Shinsei Tagawa; Kan Takeda; Hajime Yokoi; Takashi Noguchi
Journal:  J Gastroenterol Hepatol       Date:  2007-12-13       Impact factor: 4.029

8.  Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma.

Authors:  Feng Wu; Zhi-Biao Wang; Wen-Zhi Chen; Hui Zhu; Jin Bai; Jian-Zhong Zou; Ke-Quan Li; Cheng-Bing Jin; Fang-Lin Xie; Hai-Bing Su
Journal:  Ann Surg Oncol       Date:  2004-11-15       Impact factor: 5.344

9.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

10.  A NEW METHOD FOR THE GENERATION AND USE OF FOCUSED ULTRASOUND IN EXPERIMENTAL BIOLOGY.

Authors:  J G Lynn; R L Zwemer; A J Chick; A E Miller
Journal:  J Gen Physiol       Date:  1942-11-20       Impact factor: 4.086

View more
  49 in total

Review 1.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

Review 2.  [Interventional procedures for hepatic metastases].

Authors:  T Helmberger
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

Review 3.  High-Intensity Focused Ultrasound: Current Status for Image-Guided Therapy.

Authors:  Alexander Copelan; Jason Hartman; Monzer Chehab; Aradhana M Venkatesan
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 4.  Image-guided thermal ablation of benign thyroid nodules.

Authors:  Anna Pisani Mainini; Cristian Monaco; Lorenzo Carlo Pescatori; Chiara De Angelis; Francesco Sardanelli; Luca Maria Sconfienza; Giovanni Mauri
Journal:  J Ultrasound       Date:  2016-10-21

5.  Magnetic resonance temperature imaging-based quantification of blood flow-related energy losses.

Authors:  Christopher Dillon; Robert Roemer; Allison Payne
Journal:  NMR Biomed       Date:  2015-05-14       Impact factor: 4.044

Review 6.  Ablation therapy for hepatocellular carcinoma: past, present and future perspectives.

Authors:  David J Niemeyer; Kerri A Simo; David A Iannitti; Iain H McKillop
Journal:  Hepat Oncol       Date:  2013-12-20

7.  High-intensity focused ultrasound (HIFU) for the treatment of hepatocellular carcinoma: is it time to abandon standard ablative percutaneous treatments?

Authors:  Claudio Zavaglia; Andrea Mancuso; Antonella Foschi; Antonio Rampoldi
Journal:  Hepatobiliary Surg Nutr       Date:  2013-08       Impact factor: 7.293

8.  Can we ablate liver lesions close to large portal and hepatic veins with MR-guided HIFU? An experimental study in a porcine model.

Authors:  Ulrik Carling; Leonid Barkhatov; Henrik M Reims; Tryggve Storås; Frederic Courivaud; Airazat M Kazaryan; Per Steinar Halvorsen; Eric Dorenberg; Bjørn Edwin; Per Kristian Hol
Journal:  Eur Radiol       Date:  2019-02-08       Impact factor: 5.315

Review 9.  High intensity focused ultrasound, liver disease and bridging therapy.

Authors:  Luigi Mearini
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma.

Authors:  Tan To Cheung; Sheung Tat Fan; Ferdinand S K Chu; Caroline R Jenkins; Kenneth S H Chok; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; See Ching Chan; Thomas C C Yau; Ronnie T P Poon; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-04       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.